It has been proposed as effective in SLE as well [10] given that the antibody depletes pDCs, inhibits TLR7- and TLR9-stimulated IFNα production, and eliminates the IFN signature ex vivo in SLE patients. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.